Showing results (41-50 of 105) with videos related to
Sort By:
Pageof 11
The AAPS Journal|August 31, 2013
A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokineticsXiaoying Chen, Timothy Hickling, Eugenia Kraynov, et al.American Journal of Physiology. Endocrinology and Metabolism|February 8, 2002
Double isotope tracer method for measuring fractional zinc absorption: theoretical analysisGiovanni Sparacino, David M Shames, Paolo Vicini, et al.Clinical Pharmacology and Therapeutics|August 1, 2017
Dose-Exposure-Response Relationship of the Investigational Anti-Interleukin-13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled AsthmaPaul G Baverel, Nicholas White, Paolo Vicini, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain dispositionQingyu Zhou, Ping Guo, Gary D Kruh, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 29, 2014
Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinaseShinji Yamazaki, Justine L Lam, Helen Y Zou, et al.Journal of Pharmacokinetics and Pharmacodynamics|October 24, 2003
Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulinOle Østerberg, Lars Erichsen, Steen H Ingwersen, et al.Annals of Biomedical Engineering|March 7, 2007
Kinetic modeling of contrast-enhanced MRI: an automated technique for assessing inflammation in the rheumatoid arthritis wristMatthew L Zierhut, Jill C Gardner, Mary E Spilker, et al.The Journal of Pharmacology and Experimental Therapeutics|July 31, 2014
Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1Shinji Yamazaki, Justine L Lam, Helen Y Zou, et al.Biophysical Journal|November 8, 2005
Catch-bond model derived from allostery explains force-activated bacterial adhesionWendy Thomas, Manu Forero, Olga Yakovenko, et al.Journal of the Royal Society, Interface|September 22, 2017
A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibitionChang Gong, Oleg Milberg, Bing Wang, et al.Pageof 11